Ascentage Pharma Group International (NASDAQ:AAPG - Get Free Report)'s share price reached a new 52-week high on Tuesday . The stock traded as high as $27.18 and last traded at $26.82, with a volume of 1315 shares changing hands. The stock had previously closed at $25.22.
Analysts Set New Price Targets
Separately, JPMorgan Chase & Co. started coverage on Ascentage Pharma Group International in a report on Thursday, March 27th. They set an "overweight" rating for the company.
Read Our Latest Analysis on AAPG
Ascentage Pharma Group International Stock Down 1.1%
The firm has a 50-day simple moving average of $23.12.
Hedge Funds Weigh In On Ascentage Pharma Group International
A hedge fund recently bought a new stake in Ascentage Pharma Group International stock. Monashee Investment Management LLC acquired a new stake in Ascentage Pharma Group International (NASDAQ:AAPG - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 159,942 shares of the company's stock, valued at approximately $3,511,000. Monashee Investment Management LLC owned approximately 0.18% of Ascentage Pharma Group International at the end of the most recent quarter.
About Ascentage Pharma Group International
(
Get Free Report)
Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.
See Also
Before you consider Ascentage Pharma Group International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascentage Pharma Group International wasn't on the list.
While Ascentage Pharma Group International currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
